From: The association between cystatin C and COPD: a meta-analysis and systematic review
Author | Year | Study design | Country | Ethnicity | Sample | Sample size | Assay method | Cys C Concentration (mean±SD, mg/L) | Subjects(% men) | Age (mean±SD or median (range), year) | NOS score | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | Case | Control | SCOPD | AECOPD | Control | |||||||||
Qu et al [37] | 2010 | Case-control | China | Asian | serum | 70 | 30 | ELISA | SCOPD(70)1.76±0.62 | 0.98±0.51 | 62.3/NA/66.7 | 64.60±10.50 | NA | 63.50±9.20 | 6 |
Rokadia et al [38] | 2012 | Cross-sectional | USA | Caucasian | serum | 374 | 5264 | immunonephelometry | All(374)0.978±0.34;Emphysema(120)1.139±0.24;Chronic bronchitis(254)0.902±0.35 | 0.883±0.58 | 36.6/49.3 | 52.4 | 41.1 | 8 | |
Sun et al [39] | 2013 | Case-control | China | Asian | serum | 84 | NA | immunonephelometry | SCOPD(30)0.95±0.23; AECOPD(54)1.12±0.26 | NA | 70.0/68.5/NA | 64.17±10.03 | 66.98±8.07 | NA | 6 |
Zhang et al [27] | 2014 | Case-control | China | Asian | serum | 129 | 122 | immunonephelometry | SCOPD(129)0.115±0.05 | 0.105±0.03 | 100.0/NA/100.0 | 81.78± 6.68 | NA | 80.26±6.81 | 8 |
Zhang et al [29] | 2014 | Case-control | China | Asian | serum | 392 | 151 | immunonephelometry | All(392)1.04±0.21;SCOPD(299)1.03±0.21;AECOPD(93)1.09±0.22 | 0.84±0.18 | 96.1/73.1/55.0 | 65 (36-86) | 65 (44-81) | 63±6.00 | 8 |
Yoshizawa et al [40] | 2015 | Case-control | Japan | Asian | serum | 108 | 73 | immunonephelometry | SCOPD(108)1.2±0.4 | 0.9±0.2 | 83.3/NA/49.3 | 74.3±7.1 | NA | 71.8±7.3 | 9 |
Liu et al [41] | 2015 | Case-control | China | Asian | serum | 132 | 36 | ELISA | All(132)0.1287±0.0377;SCOPD(60)0.1254±0.0309;AECOPD(72)0.1315±0.0425 | 0.1084±0.0267 | 52.8/51.7/55.5 | 60-69 | 62-71 | 60-68 | 7 |
Zhang et al [42] | 2015 | Cohort | China | Asian | serum | 90 | 90 | immunonephelometry | AECOPD(90)1.31±0.30 | 0.87±0.13 | NA/78.9/77.8 | NA | 63±7 | 62±7 | 7 |
Zhou et al [43] | 2016 | Case-control | China | Asian | serum | 168 | NA | immunonephelometry | SCOPD(60)0.94±0.22;AECOPD(108) 1.13±0.25 | NA | 70/67.6/NA | 65.20±10.10 | 67.11±8.11 | NA | 6 |
Ni et al [44] | 2017 | Case-control | China | Asian | serum | 90 | 45 | immunonephelometry | All(90)0.1409±0.0197;SCOPD(45)0.1339±0.0154;AECOPD(45)0.1478±0.0212 | 0.1045±0.0209 | 54.4/53.3 | 58.1±5.4 | 56.9±4.9 | 7 | |
Chen et al [45] | 2017 | Case-control | China | Asian | serum | 95 | 20 | ELISA | 0.13299±0.01121 | 0.10617±0.02132 | 56.8/63.3 | 64.04±3.12 | 63.76±2.44 | 7 | |
Cui et al [46] | 2018 | Case-control | China | Asian | serum | 157 | 50 | immunonephelometry | 1.06±0.41 | 0.84±0.27 | 60.5/60 | 73.2±8.2 | 70.5 ± 4.7 | 7 | |
Selda et al [31] | 2018 | Case-control | Turkey | Asian | serum | 126 | 50 | immunonephelometry | All(126)0.99±0.45;SCOPD(68)1.01±0.56;AECOPD(58)0.97±0.29 | 0.47±0.13 | 88.2/82.8/82.0 | 64.19±10.6 | 65.12±6.93 | 60.12±11.77 | 8 |
Amado et al [28] | 2018 | Cohort | Spain | Caucasian | serum | 65 | 18 | immunonephelometry | SCOPD(65)0.97±0.32 | 0.88±0.2 | 72/NA/55 | 67±7 | NA | 67±5 | 9 |
Dickson et al [30] | 2019 | Case-control | China | Asian | serum | ### | NA | immunonephelometry | SCOPD(362)1.18±0.471;AECOPD(1637)1.21±0.47 | NA | 68.5/69.5/NA | 92.97±9.83 | 72.51±10.27 | NA | 7 |